ubrogepant Ubrelvy
Selected indexed studies
- Ubrogepant: First Approval. (Drugs, 2020) [PMID:32020557]
- Diagnosis and Management of Headache: A Review. (JAMA, 2021) [PMID:33974014]
- Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA. (Lancet, 2023) [PMID:37979595]
_Worker-drafted node — pending editorial review._
Connections
ubrogepant Ubrelvy is a side effect of
Sources
- Migraine overview and summary of current and emerging treatment options. (2019) pubmed
- Ubrogepant. (2012) pubmed
- Ubrogepant. (2006) pubmed
- Ubrogepant: First Approval. (2020) pubmed
- Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA. (2023) pubmed
- Ubrogepant for the Treatment of Migraine. (2019) pubmed
- Diagnosis and Management of Headache: A Review. (2021) pubmed
- The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. (2021) pubmed
- Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine: A Systematic Review and Meta-analysis. (2021) pubmed
- Safety and tolerability of ubrogepant for the acute treatment of migraine in participants taking atogepant for the preventive treatment of episodic migraine: Results from the TANDEM study. (2025) pubmed